English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective:This study aimed to investigate the pleotropic effects of telmisartan against the metabolic derangement, and the maturation of the inflammasome (interleukins 1β and 18) that associated with NAFLD.Methods:This open label clinical trial was carried in the Department of Pharmacology, College of Medicine at University of Sulaimani in cooperation with the Shar Hospital in the Sulaimani-Iraq. A total number of 51 NAFLD patients were recruited and grouped randomly into Group I (n=25) treated with placebo and Group II (n=26) treated with telmisartan (20 mg single oral dose, daily) for 8 weeks. Anthropometric measurements, fasting lipid profile and glucose levels, hematological indices, hepatic-fibrosis assessment, and inflammatory (including interleukins 1β and -18) markers were determined.Results:Telmisartan significantly reduced the waist circumference, blood pressure, triglyceride-glucose index, and aspartate transaminase enzyme. A significant high value of hepatic fibrosis in Group I patients compared with Group II patients was observed. Telmisartan significantly reduced the inflammasome markers, granulocyte number and without producing a significant effect against platelet count.Conclusions:Short-term therapy with low dose telmisartan can suppresses the maturation of inflammasome manifested by significant low levels of serum IL-1β and IL-18. This effect associated with improvement of the metabolic derangement and decreasing the liver fibrosis in NAFLD.

electronic journal of general medicine

Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study